Tenaya News & Updates

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with ...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: T...

Sep 05, 2022 • Yahoo Finance

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits...

Jun 03, 2026 • Markets Insider

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d...

Jun 02, 2026 • Markets Insider

Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?

Tenaya Therapeutics recently reported a reduced net loss of US$19.27 million for the first quarter o...

May 11, 2026 • Yahoo Finance

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

ASGCT Presentations Include Preclinical Data for TN-401 PKP2 and DWORF Gene Therapy Programs and AAV...

May 03, 2022 • Nasdaq

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a c...

Dec 17, 2024 • Seeking Alpha

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including ch...

Jun 04, 2026 • The Globe and Mail

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

Tenaya Therapeutics, Inc. announced that it will present five abstracts at the American Society of G...

May 13, 2025 • Nasdaq

Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Tenaya uses human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high throughp...

Mar 05, 2026 • Benzinga.com

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne...

Apr 26, 2026 • manilatimes

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TN...

Dec 10, 2025 • Yahoo Finance

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

An archived replay of the webcast will be available on the Tenaya website for approximately 30 days ...

May 29, 2026 • Markets Insider

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th ...

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNY...

May 02, 2023 • Yahoo Finance

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Deve...

Mar 24, 2025 • Taiwan News

Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lig...

Jun 04, 2026 • The Globe and Mail

Tenaya Therapeutics Shareholders Approve Expanded Equity Incentive Plan

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including ch...

May 30, 2026 • The Globe and Mail

Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates

Tenaya Therapeutics (TNYA) delivered earnings and revenue surprises of +4.26% and -97.75%, respectiv...

May 06, 2026 • Yahoo Finance

Tenaya tackles genetic heart condition after thorough screening process nails down target

Dilated cardiomyopathy (DCM) is a genetic heart condition that both stretches and thins the left ven...

Jul 11, 2022 • FierceBiotech

Tenaya gene therapy for deadly heart condition boosts long-term survival in mice

Tenaya Therapeutics’ gene therapy for an inherited heart condition that can cause sudden death app...

Mar 18, 2024 • FierceBiotech

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 9.02%

As of Monday, May 18, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 9.02%, which has ...

May 18, 2026 • American Association of Individual Investors

Tenaya, Alnylam in Cardiovascular Disease Research Collaboration Worth Up to $1.14B

Tenaya Therapeutics and Alnylam Pharmaceuticals are collaborating on research to find treatments for...

Mar 05, 2026 • MarketWatch

Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements

Tenaya Therapeutics Inc. TNYA on Friday reported interim Phase 1b/2 RIDGE-1 data showing its TN-401 ...

May 15, 2026 • Benzinga on MSN

Alnylam’s research pact worth up to $1.1B sends Tenaya higher

Tenaya Therapeutics (TNYA) added ~10% in the premarket on Thursday after the company signed a resear...

Mar 05, 2026 • Seeking Alpha

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with ...

All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction C...

May 15, 2026 • Markets Insider

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated ...

Tenaya Management to Host Webcast Call for Analysts and Investors on Monday, November 10 at 8:00 a.m...

Nov 08, 2025 • Nasdaq

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Dec 16, 2024 • Business Insider

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnol...

Apr 28, 2022 • Business Wire

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Feb 25, 2024 • Yahoo Finance

Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Tenaya Therapeutics today and set ...

May 18, 2026 • The Globe and Mail

Tenaya Therapeutics stock hits 52-week low at $0.68 amid market challenges

In a challenging market environment, Tenaya Therapeutics, Inc. (TNYA) stock has reached a 52-week lo...

Mar 04, 2025 • Investing